Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AHACNASDAQ:MGTXNASDAQ:OPTNASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAHACAlpha Healthcare Acquisition$10.96$10.41$9.12▼$16.96$140.89MN/A341,126 shs298,128 shsMGTXMeiraGTx$6.34-2.2%$5.86$3.85▼$8.75$509.51M1.16382,939 shs408,786 shsOPTOpthea$3.41$3.41$1.79▼$6.30$524.84M1.1826,566 shsN/AVALNValneva$5.66-1.1%$6.39$3.62▼$8.66$478.23M1.8142,727 shs11,596 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAHACAlpha Healthcare Acquisition0.00%0.00%0.00%0.00%0.00%MGTXMeiraGTx-2.16%-4.37%+19.62%-16.14%+48.48%OPTOpthea0.00%0.00%0.00%0.00%+82.35%VALNValneva-1.12%-5.89%-11.97%-21.12%-20.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAHACAlpha Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AMGTXMeiraGTx3.828 of 5 stars3.52.00.04.80.02.50.6OPTOpthea0.5671 of 5 stars2.10.00.00.00.60.80.6VALNValneva2.8396 of 5 stars3.55.00.00.03.10.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAHACAlpha Healthcare Acquisition 0.00N/AN/AN/AMGTXMeiraGTx 3.00Buy$24.00278.55% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideVALNValneva 3.00Buy$15.50174.05% UpsideCurrent Analyst Ratings BreakdownLatest AHAC, VALN, OPT, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.005/8/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/15/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/9/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/31/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.003/25/2025OPTOptheaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.003/25/2025OPTOptheaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$8.00 ➝ $1.003/24/2025OPTOptheaLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025OPTOptheaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/24/2025VALNValnevaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAHACAlpha Healthcare AcquisitionN/AN/A$0.12 per share92.25$0.39 per shareN/AMGTXMeiraGTx$33.28M15.31N/AN/A$0.87 per share7.29OPTOpthea$120K4,373.61N/AN/A($0.56) per share-6.09VALNValneva$183.52M2.62$0.10 per share57.52$2.41 per share2.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAHACAlpha Healthcare Acquisition$1.42MN/A0.00∞N/AN/AN/AN/AN/AMGTXMeiraGTx-$147.79M-$2.32N/A16.68N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)OPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/A8/28/2025 (Estimated)VALNValneva-$13.25M-$1.19N/AN/AN/A-43.08%-43.05%-16.23%8/12/2025 (Estimated)Latest AHAC, VALN, OPT, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGTXMeiraGTx-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million5/7/2025Q1 2025VALNValneva-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAHACAlpha Healthcare AcquisitionN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAHACAlpha Healthcare AcquisitionN/A2.102.10MGTXMeiraGTx2.341.531.51OPTOptheaN/A1.57N/AVALNValneva0.922.702.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAHACAlpha Healthcare Acquisition19.00%MGTXMeiraGTx67.48%OPTOpthea55.95%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipAHACAlpha Healthcare AcquisitionN/AMGTXMeiraGTx7.50%OPTOpthea3.20%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAHACAlpha Healthcare AcquisitionN/A12.86 millionN/ANot OptionableMGTXMeiraGTx30080.36 million74.34 millionOptionableOPTOpthea8153.91 million148.99 millionNot OptionableVALNValneva70085.09 million72.41 millionNot OptionableAHAC, VALN, OPT, and MGTX HeadlinesRecent News About These CompaniesValneva (NASDAQ:VALN) Shares Gap Down - Should You Sell?June 17, 2025 | marketbeat.comValneva SE (NASDAQ:VALN) Sees Large Drop in Short InterestJune 14, 2025 | marketbeat.comValneva (NASDAQ:VALN) Stock Price Down 4% - Here's What HappenedJune 12, 2025 | marketbeat.comChikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measureJune 10, 2025 | indiaeducationdiary.inUK's MHRA suspends Valneva's chikungunya vaccine for elderlyJune 10, 2025 | reuters.comValneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in ChildrenJune 10, 2025 | pharmexec.comUK restricts use of Valneva chikungunya vaccine for safety reviewJune 10, 2025 | yahoo.comUK's MHRA suspends Valneva's chikungunya vaccine for elderly (June 9)June 10, 2025 | msn.comValneva reports data from Phase II chikungunya vaccine trial in childrenJune 6, 2025 | finance.yahoo.comValneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®June 5, 2025 | globenewswire.comValneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate UpdateJune 4, 2025 | globenewswire.comValneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?June 3, 2025 | marketbeat.comValneva SE (NASDAQ:VALN) Sees Large Decrease in Short InterestJune 2, 2025 | marketbeat.comValneva to Participate at U.S. and European Investor Conferences in JuneMay 26, 2025 | globenewswire.comUS CDC accepts recommendations for chikungunya vaccinesMay 21, 2025 | msn.comLondon man among thousands who've rolled up their sleeves to trial Lyme disease vaccineMay 19, 2025 | cbc.caUS Advises Older Travelers to Avoid Chikungunya VaccineMay 16, 2025 | infectiousdiseaseadvisor.comFDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for SeniorsMay 15, 2025 | pharmexec.comFDA, CDC recommend pause in Valneva chikungunya vaccine for older adultsMay 14, 2025 | cidrap.umn.eduU.S. Advises Older Travelers to Avoid Chikungunya VaccineMay 13, 2025 | usnews.comFDA warns seniors to avoid this vaccine after deadly complicationsMay 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Industrials Stocks Standing Out for Growth and Analyst OptimismBy Nathan Reiff | June 4, 2025View 3 Industrials Stocks Standing Out for Growth and Analyst OptimismSilver's Options Sizzle: Are Traders Betting on a Breakout?By Jeffrey Neal Johnson | June 5, 2025View Silver's Options Sizzle: Are Traders Betting on a Breakout?The Other AI Chipmaker: Why Marvell's Dip Is a BuyBy Jeffrey Neal Johnson | June 12, 2025View The Other AI Chipmaker: Why Marvell's Dip Is a BuyAT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?By Jeffrey Neal Johnson | June 5, 2025View AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?Zscaler Upgraded: Wall Street Forecasts 26% More UpsideBy Gabriel Osorio-Mazilli | June 17, 2025View Zscaler Upgraded: Wall Street Forecasts 26% More UpsideAHAC, VALN, OPT, and MGTX Company DescriptionsAlpha Healthcare Acquisition NASDAQ:AHACAlpha Healthcare Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.MeiraGTx NASDAQ:MGTX$6.34 -0.14 (-2.16%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$6.36 +0.02 (+0.24%) As of 06/20/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 06/20/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Valneva NASDAQ:VALN$5.66 -0.06 (-1.12%) Closing price 06/20/2025 03:58 PM EasternExtended Trading$5.66 0.00 (0.00%) As of 06/20/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
